Literature DB >> 11547295

Superior cavopulmonary anastomosis suppresses the activity and expression of pulmonary angiotensin-converting enzyme.

S P Malhotra1, R K Riemer, S Thelitz, Y P He, F L Hanley, V M Reddy.   

Abstract

BACKGROUND: Superior cavopulmonary anastomosis is widely used for palliation of various forms of univentricular heart defects. However, clinically significant pulmonary arteriovenous malformations develop in 15% to 25% of patients after surgery.
OBJECTIVE: To assess altered regulation of pulmonary vascular tone caused by superior cavopulmonary anastomosis in an ovine model.
METHODS: Lambs, aged 35 to 45 days, underwent an end-to-end anastomosis of the superior vena cava to the right pulmonary artery. In age-matched controls, a sham operation was performed. Arteriovenous malformations were detectable by contrast echocardiography by 8 weeks after surgery. Animals (n = 24) were studied at various time points after the operations. Expression of angiotensin-converting enzyme messenger RNA, protein levels, and enzyme activity were measured in lung homogenates. Levels of angiotensin II were measured by enzyme-linked immunosorbent assay.
RESULTS: Expression of angiotensin-converting enzyme messenger RNA and protein was significantly reduced at 1 to 5 weeks after superior cavopulmonary anastomosis. Angiotensin-converting enzyme activity in the right lung of animals subjected to superior cavopulmonary anastomosis was reduced 86% +/- 1% (standard deviation) compared with control values at 1 week (P =.003) and 77% +/- 8.5% at 2 weeks (P <.001) after surgery. This correlated with a 59% +/- 3.5% (P =.007) reduction in angiotensin II levels up to 5 weeks after cavopulmonary anastomosis. By 15 weeks after the operations, angiotensin II levels were equivalent to control levels (P =.19).
CONCLUSIONS: Superior cavopulmonary anastomosis causes an early reversible reduction in activity and expression of angiotensin-converting enzyme, resulting in decreased circulating levels of the vasoconstrictor angiotensin II. These results suggest that the ability of the pulmonary endothelium to regulate vascular tone is inhibited after superior cavopulmonary anastomosis. Dilation of the affected vasculature induced by cavopulmonary anastomosis may contribute to the disordered vascular remodeling observed in this setting.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11547295     DOI: 10.1067/mtc.2001.115698

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  6 in total

1.  Morphological studies of pulmonary arteriovenous shunting in a lamb model of superior cavopulmonary anastomosis.

Authors:  S M Bradley
Journal:  Pediatr Cardiol       Date:  2008-07       Impact factor: 1.655

Review 2.  Pulmonary arteriovenous malformations after the superior cavopulmonary shunt: mechanisms and clinical implications.

Authors:  Minoo N Kavarana; Jeffrey A Jones; Robert E Stroud; Scott M Bradley; John S Ikonomidis; Rupak Mukherjee
Journal:  Expert Rev Cardiovasc Ther       Date:  2014-04-23

3.  Constitutively active endothelial Notch4 causes lung arteriovenous shunts in mice.

Authors:  Doug Miniati; Eric B Jelin; Jennifer Ng; Jianfeng Wu; Timothy R Carlson; Xiaoqing Wu; Mark R Looney; Rong A Wang
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-11-20       Impact factor: 5.464

Review 4.  Is the Hepatic Factor a miRNA that Maintains the Integrity of Pulmonary Microvasculature by Inhibiting the Vascular Endothelial Growth Factor?

Authors:  Joseph J Vettukattil
Journal:  Curr Cardiol Rev       Date:  2017

Review 5.  Pulmonary Vascular Sequelae of Palliated Single Ventricle Circulation: Arteriovenous Malformations and Aortopulmonary Collaterals.

Authors:  Andrew D Spearman; Salil Ginde
Journal:  J Cardiovasc Dev Dis       Date:  2022-09-17

6.  Endostatin, an inhibitor of angiogenesis, decreases after bidirectional superior cavopulmonary anastamosis.

Authors:  Aida Field-Ridley; Ritva Heljasvaara; Taina Pihlajaniemi; Ian Adatia; Christine Sun; Roberta L Keller; Wen Hui Gong; Sanjeev Datar; Peter Oishi; Jeffrey R Fineman
Journal:  Pediatr Cardiol       Date:  2012-09-08       Impact factor: 1.655

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.